[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367557-105":59,"doc-detail-367557-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanosecond-pulsed-electric-field-ablation-as-first-line-curative-therapy-for-hepatocellular-carcinoma-in-high-risk-locations-prospective-multicenter-trial","Nanosecond pulsed electric field ablation as first-line curative therapy for hepatocellular carcinoma in high-risk locations - Prospective multicenter trial","","Nanosecond pulsed electric field ablation (nsPEF) is a nonthermal ablation modality designed to eradicate tumors near critical structures. A prospective multicenter trial evaluated nsPEF for hepatocellular carcinoma (HCC) in high-risk locations in five hospitals in China. Patients with HCC meeting the Milan criteria and located immediately adjacent to key structures (\u003C0.5 cm)—including the portal vein, hepatic vein, diaphragm, gastrointestinal tract, liver capsule, or gallbladder—were enrolled. Complete ablation at 1 month and safety outcomes were primary endpoints; local tumor progression, recurrence-free survival, and overall survival were secondary endpoints. Between March 2020 and June 2022, 192 patients were enrolled with a 99.5% technical success rate and 91.7% complete ablation across 217 tumors. Complete ablation at 1 month was higher for tumors \u003C2 cm versus ≥2 cm (90.1% vs. 71.7%). No periprocedural thermal damage was observed; grade ≥3 treatment-related adverse events occurred in 5.6% of patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanosecond-pulsed-electric-field-ablation-as-first-line-curative-therapy-for-hepatocellular-carcinoma-in-high-risk-locations-prospective-multicenter-trial/367557/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanosecond-pulsed-electric-field-ablation-as-first-line-curative-therapy-for-hepatocellular-carcinoma-in-high-risk-locations-prospective-multicenter-trial/367557.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary objective of the prospective multicenter study?","Question",{"text":112,"@type":113},"To evaluate the efficacy and safety of nanosecond pulsed electric field ablation (nsPEF) as first-line curative therapy for hepatocellular carcinoma in high-risk locations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the enrolled patients and what locations were considered high-risk?",{"text":117,"@type":113},"Patients with HCC fulfilling the Milan criteria and immediately adjacent to critical structures (\u003C0.5 cm) such as the portal vein, hepatic vein, diaphragm, gastrointestinal tract, liver capsule, or gallbladder were enrolled.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key efficacy and safety findings?",{"text":121,"@type":113},"The study reported a 99.5% technical success rate and 91.7% complete ablation of 217 tumors, with no periprocedural thermal damage observed. Grade ≥3 treatment-related adverse events occurred in 5.6% of patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367557,1790195478,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Nanosecond pulsed electric field ablation as first-line curative therapy for hepatocellular carcinoma in high-risk locations a prospective multicenter  \nMin Xu, MDa , Wu Zhang, PhDb , Danxia Xu, MDa , Gang Dong, MDc , Zhigang Ren, PhDd , Tuerganaili Aji, PhDe , Jiansong Ji, PhDf, Qiyu Zhao, PhDa , Jinhua Pan, PhDa , Xinhua Chen, PhDg , Tian’An Jiang, PhDa ,*  \nBackground: Preclinical studies have shown that nanosecond pulsed electric field ablation (nsPEF) is a novel nonthermal ablation modality that can eradicate tumors near critical structures. We conducted the prospective multicenter trial to investigate the efficacy and safety of nsPEF for hepatocellular carcinoma (HCC) in high-risk locations.  \nMaterials and methods: This study was conducted at five hospitals in China. Patients with HCC fulfilling the Milan criteria and located immediately adjacent to (\u003C0 .5 cm) the portal vein, hepatic vein, diaphragm, gastrointestinal tract, liver capsule, or gallbladder were enrolled. The primary endpoint was the complete ablation rate at 1 month, and adverse events. The secondary endpoints included local tumor progression (LTP), recurrence-free survival (RFS), and overall survival.  \nResults: From March 2020 to June 2022, 192 patients were enrolled (148 males [77 . 1%]; median age 58.5 years [interquartile range, 51.0–66.0 years]) . The median follow-up duration was 33.5 months. The technical success rate was 99.5% . Complete ablation was achieved in 91.7% of the 217 tumors. Complete ablation rates at 1 month were significantly higher in tumors \u003C2 cm vs. ≥2 cm (90 . 1% vs. 71.7%, P = 0.002) . The estimated 1- , 2-and 3-year cumulative incidences of LTP were 9.8%, 13.8%, and 15.7%, respectively. The maximum tumor diameter (hazard ratio [HR] = 2.62, P = 0.014) and age (HR = 0.42, P = 0.026) were independent predictive factors for LTP. The RFS rates at 1- , 2-and 3-year were 72.2%, 51.7%, and 43.5%, respectively. No periprocedural thermal damage was observed. Grade ≥3 treatment-related adverse events occurred in nine (5 .6%) patients. Conclusion: To our knowledge, this was the first prospective trial demonstrating that nsPEF was effective and relatively safe for HCC in high-risk locations, and may serve as an alternative therapeutic option for HCC suboptimal for thermal ablation. Keywords: electroporation, hepatocellular carcinoma, minimally invasive procedures  \naDepartment of Ultrasound Medicine, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, bShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University, Shulan International Medical College, Hangzhou, China, cDepartment of Ultrasound, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, dDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, eDepartment of Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China, fKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China and gDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China  \nM.X. and W.Z. have contributed equally to this work.  \nSponsorships or competing interests that may be relevant to content are disclosed at the end of this article.  \n[This study has been registered at ClinicalTrials.gov](This study has been registered at ClinicalTrials.gov) (identifier: NCT04309747).  \n*Corresponding author. Address: Department of Ultrasound Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China. Tel.: +86 87236515. E-mail: [tiananjiang@zju.edu.cn](tiananjiang@zju.edu.cn) (T. Jiang). Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attributio","cbCaiq3s9nRPClwo","https://ap.wps.com/l/cbCaiq3s9nRPClwo","pdf",1803764,"English","# Background\n# Materials and methods\n# Results\n## Efficacy outcomes\n## Safety outcomes\n# Conclusion","[{\"question\":\"What was the primary objective of the prospective multicenter study?\",\"answer\":\"To evaluate the efficacy and safety of nanosecond pulsed electric field ablation (nsPEF) as first-line curative therapy for hepatocellular carcinoma in high-risk locations.\"},{\"question\":\"Who were the enrolled patients and what locations were considered high-risk?\",\"answer\":\"Patients with HCC fulfilling the Milan criteria and immediately adjacent to critical structures (\\u003c0.5 cm) such as the portal vein, hepatic vein, diaphragm, gastrointestinal tract, liver capsule, or gallbladder were enrolled.\"},{\"question\":\"What were the key efficacy and safety findings?\",\"answer\":\"The study reported a 99.5% technical success rate and 91.7% complete ablation of 217 tumors, with no periprocedural thermal damage observed. Grade ≥3 treatment-related adverse events occurred in 5.6% of patients.\"}]","Nanosecond pulsed electric field ablation as first-line curative therapy for hepatocellular carcinoma in high-risk locations - Prospective multicenter trial | PDF",1790171363,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/594a93f907f03e9c452ceeec12ca45ac.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9dd3c76c52284d19fb5734f7a1d9950.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/133e840a6fc8d659c6999fffd19b1285.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/525d2ec40d686ac4369f135c291a815d.webp",980,1306]